financetom
Business
financetom
/
Business
/
Insurer AIG posts higher quarterly profit on underwriting strength
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Insurer AIG posts higher quarterly profit on underwriting strength
Aug 6, 2025 1:38 PM

Aug 6 (Reuters) - American International Group ( AIG )

reported a higher second-quarter profit on Wednesday, powered by

strong underwriting gains and higher returns on investments.

Insurers like AIG and Travelers Cos ( TRV ) are benefiting

as businesses and individuals have maintained spending on

insurance against the backdrop of economic uncertainty.

"We continued to make significant progress on our long-term

strategic, operational and financial objectives while navigating

a dynamic macroeconomic environment," CEO Peter Zaffino said in

a statement.

General insurance net premiums written, on a comparable

basis, rose to $6.88 billion in the three months ended June 30.

General insurance underwriting income soared 46% to $626

million.

AIG's general insurance combined ratio came in at 89.3% on

an adjusted basis, compared with 92.5% a year earlier. A ratio

below 100 signifies that the insurer earned more from premiums

than it paid out in claims.

A rebound in the stock markets following tariffs-related

volatility has also helped insurers boost their investment

income.

Net investment income jumped 48% to $1.47 billion in the

second quarter, driven by a change in the fair value of AIG's

equity in Corebridge and higher income on available for sale

fixed maturity securities.

The company retains a stake in Corebridge, the life and

retirement insurer it spun off in 2022.

AIG posted catastrophe-related charges of $170 million in

the quarter, down from $330 million in the year-ago period.

The company - one of the world's largest commercial insurers

- reported adjusted after-tax income attributable to common

shareholders of $1.04 billion, or $1.81 per share, compared with

$771 million, or $1.16 per share, a year earlier.

Shares of the company have gained nearly 8% in 2025,

outperforming the broader Dow Jones U.S. Select Insurance Index

.

(Reporting by Pritam Biswas in Bengaluru; Editing by Sriraj

Kalluvila)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ashland Completes $10 Million Expansion of Pharmaceutical Production Plant in Brazil
Ashland Completes $10 Million Expansion of Pharmaceutical Production Plant in Brazil
Apr 1, 2025
08:33 AM EDT, 04/01/2025 (MT Newswires) -- Ashland (ASH) said Tuesday it has completed a $10 million expansion of its pharmaceutical production plant in Cabreuva, Brazil, to meet rising demand for coated tablets in Latin America and Brazil. As part of the investment, the company has also upgraded its equipment for microbial protection in personal care applications at the research...
i-80 Gold Up 9% Pre-market as Q4 Loss Narrows, Releases Growth and Recapitalization Plans
i-80 Gold Up 9% Pre-market as Q4 Loss Narrows, Releases Growth and Recapitalization Plans
Apr 1, 2025
08:33 AM EDT, 04/01/2025 (MT Newswires) -- i-80 Gold ( IAUX ) was up 9% in pre-market Nasdaq trading after the company overnight Monday said its fourth-quarter loss narrowed despite weaker revenue and that it plans five new mining projects to boost gold production to as much as 500,000 ounces annually by the end of the decade. The Nevada miner...
Brookfield Asset Management to Buy Majority Stake in Angel Oak
Brookfield Asset Management to Buy Majority Stake in Angel Oak
Apr 1, 2025
08:33 AM EDT, 04/01/2025 (MT Newswires) -- Brookfield Asset Management ( BAM ) has agreed to acquire a majority stake in asset manager Angel Oak, the companies said Tuesday. Financial terms were not provided. Angel Oak, which manages over $18 billion in assets, will join Brookfield's credit platform but will continue to operate independently under its existing leadership, according to...
Organon Acquires Tofidence for Intravenous Infusion in US
Organon Acquires Tofidence for Intravenous Infusion in US
Apr 1, 2025
08:32 AM EDT, 04/01/2025 (MT Newswires) -- Organon (OGN) said Tuesday it acquired from Biogen (BIIB) the regulatory and commercial rights to Tofidence for intravenous infusion in the US. Tofidence, a biosimilar to Actemra, is indicated for the treatment of arthritis and COVID-19, Organon said. The company said the deal includes an upfront payment to Biogen, with Organon assuming the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved